Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Glucose Health, Inc. (GLUC)

Other OTC - Other OTC Delayed Price. Currency in USD
0.7200+0.0202 (+2.89%)
At close: 02:47PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6998
Open0.6750
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.6750 - 0.7200
52 Week Range0.3220 - 2.0700
Volume1,430
Avg. Volume12,770
Market Cap1.072M
Beta (5Y Monthly)3.09
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for GLUC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • GLUCOSE HEALTH INC
    AME: Lowering target price to $111.00AMETEK INC has an Investment Rating of SELL; a target price of $111.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    IMPORTANT CORPORATE DEVELOPMENTS - GLUCOSE HEALTH, INC. (OTC: GLUC)

    Bentonville, AR, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) ("Company") confirms the following important corporate developments. Three outstanding candidates have now accepted nominations to serve as independent directors of the Company. Charters for the enactment of Audit, Compensation and Corporate Governance/Nominations committees, each comprised, or majority comprised, of the independent directors, have been established. The Company appointed a Public Company Accounti

  • GlobeNewswire

    Glucose Health, Inc. (OTC: GLUC) Quarterly Report – Q3 Fiscal 2022

    BENTONVILLE, AR , Oct. 24, 2022 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) ("Company") is pleased to highlight selected financial information from its third Quarterly Report of Fiscal 2022, for the period ended September 30, 2022, posted today at OTCMarkets.com. Q3 2022 Revenue of $340,681 vs. $234,930 for Q3 2021 = a 45% increase.Q3 2022 Gross Profit of $153,789 vs. $62,032 for Q3 2021 = a 148% increase.Q3 2022 Net Income of $8,091 vs. Q3 2021 Net Loss of $133,160. The Company additio

  • GlobeNewswire

    Glucose Health, Inc. Corporate Update

    BENTONVILLE, AR, March 24, 2022 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC Pink: GLUC) ("Company") today provided the following corporate update, in response to requests from shareholders and interested parties for clarification of recent corporate events. John Fieldly, the current Chief Executive Officer of Celsius Holdings, Inc. (Celsius), Hal Kravitz, a current member of the Board of Directors of Celsius, and Gerry David, the former Chief Executive Officer of Celsius, comprised the indepen

Advertisement
Advertisement